Knox, J. J., O'Kane, G., King, D., Laheru, D., Habowski, A. N., Yu, K., Perez, K., Aguirre, A. J., Coyne, Z., Harvey, H., McLaughlin, R. A., Jang, R. W., Grant, R. C., Elimova, E. C., Renouf, D. J., Fischer, S., Duan, K., Ramotar, S., Jang, G. H., Zhang, A., Devoe, C. E., Singh, H., Pishvaian, M. J., Froeling, F. E., Saif, M. W., O'Reilly, E. M., Tsang, E. S., Wolpin, B. M., Wilson, J. M., Dodd, A., Pugh, T. J., Ye, X. Y., Gallinger, S., Tuveson, D. A., Notta, F., Jaffee, E. M. (2025). PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00436